CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Open to females ages 18-70

• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
• Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer
• FIGO Stage III or IV
• Positive for claudin 6 (CLDN6) expression
• Adequate organ function

• Clear cell, mucinous, sarcomatous, mixed histology, low-grade/borderline, or non-epithelial ovarian cancers
• Prior systemic treatment for the disease under study
• Prior surgery
• Prior radiation therapy to the abdomen or pelvis
• Current recipient or receipt within 5-half-lives of C1D1 of chemotherapy, biologic/targeted therapy, immunomodulator therapy for any disease indication
• Active, progressive, or symptomatic brain metastases
• Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases
• Pregnant or breastfeeding women